Wednesday, July 8, 2026

pharma · Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis (PFIC) · MIRM

Mirum Pharmaceuticals International

Mirum Pharmaceuticals International is a pharma organization headquartered in Foster City, USA. It trades on NYSE under ticker MIRM. Primary therapeutic focus areas include Alagille Syndrome, Progressive Familial Intrahe

989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US HQ
2018 Founded
436 Employees
Public company Type
MIRM · NYSE Ticker
Company details
Status
Public
HQ
989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US
Founded
2018
Employees
436
Programs
25
Drugs
10
Patents
4
Clinical program

Cholic Acid

Phase 3 · small molecule · Bile Acid Synthesis Defect

Cholic Acid for Bile Acid Synthesis Defect is a Phase 3 program (small_molecule) at Mirum Pharmaceuticals International B.V. with 1 ClinicalTrials.gov record(s).

Internal code CAC-002-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Mirum Pharmaceuticals International B.V.
Phase
Phase 3
Modality
small_molecule
Indication
Bile Acid Synthesis Defect
Status
completed
Trials
1